BreathID® Hp System
DeviceBreath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
NCT Number: NCT02905825
Clinical Study to Confirm Safety and Accuracy in Detection of H. pylori with 13C-Urea Breath Test using the BreathID® Hp and BreathID® Hp Lab Systems in the Pediatric Population
Looking for future studies?
Notify Me3 year–18 year
All sexes
Interventional
Phase 3
Assaf Harofe Medical Center, Tzrifin, Israel
Pediatric subjects with indication for H.pylori testing, will be tested with both stool antigen as a reference standard and a urea breath test using the BreathID® Hp and BreathID® Hp Lab Systems. The BreathID® Hp system continuously measures breath via a nasal cannula and the BreathID® Hp Lab System measures breath collection bags before and after ingestion of a solution with enriched carbon 13 urea and citric acid. The stool sample will be provided within a week of the breath tests and will be analyzed by a central laboratory. Safety and overall efficacy will be assessed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
Each subject was asked to perform a stool test in parallel to the breath test.
Other names: Stool Antigen Test
Time frame: 24 hours
Number of participants with reported adverse events after performing urea breath test
Time frame: 1 week
Percentage of agreement between stool test reference standard and continuous urea breath test in assessing presence or absence of Helicobacter pylori infection
Time frame: 1 week
Percentage of agreement between stool test reference standard and breath bags from urea breath test in assessing presence or absence of Helicobacter pylori infection
Meridian Bioscience, Inc.
Industry
Clinical Confirmation Study to Confirm Safety and Presence of H. Pylori With 13C-Urea Breath Test Using the BreathID® Hp and BreathID® Hp Lab Systems in the Pediatric Population
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06561711
Helicobacter Pylori Infection, cyclopia sequence
Beijing, Beijing Municipality, China
View Trial DetailsNCT07122284
Gut Microbiota, Helicobacter Pylori Infection
Xiamen, Fujian, China
View Trial DetailsNCT06340334
Furazolidone, Helicobacter Pylori Infection
Nanjing, China
View Trial DetailsNCT06412588
Helicobacter Pylori Infection
Nanjing, Jiangsu, China
View Trial Details